Capability
Preclinical Strategy
BridgeLine Translational's Preclinical Strategy is a study-by-study development plan from discovery through IND-enabling. Model selection, endpoints, budgets, CRO selection, and regulatory strategy, shaped to the decision in front of the program.
When to engage
Common engagements
Three situations where Preclinical Strategy engagements usually start.
For teams with discovery data
“What does our preclinical package need to look like?”
A program with proof-of-principle data and no development plan. The work delivers a named study sequence, CRO shortlist, budget, timeline, and decision gates.
For teams heading into regulatory
“What does a successful pre-IND meeting look like?”
Nonclinical package gap analysis, dose rationale framework (MABEL/NOAEL), pre-IND briefing document outline, and a question list aligned to FDA or EMA expectations.
For teams with a plan already
“Is our current plan IND-adequate?”
Independent review of the existing plan against regulatory expectations and likely reviewer questions. Output is a gap register with named remediation steps.
What's inside
Deliverables
Study-level specificity, regulatory alignment, and board-ready format.
Indication and positioning
- Target rationale connecting mechanism to clinical differentiation
- Competitive landscape with explicit positioning against current SOC and pipeline
- Indication selection grounded in unmet need, feasibility, and market opportunity
- Narrative that connects target, indication, and timing into one story
Study-by-study plan
- Model selection with species, strain, and scientific rationale
- Endpoint design with predefined success criteria and go/no-go triggers
- Timeline with milestones, decision gates, and critical-path dependencies
- Budget with quarterly capital requirements and burn-rate projections
- CRO shortlists with selection criteria and specific recommendations
- Biomarker strategy with sample types, timepoints, and connection to future clinical endpoints
Regulatory path
- IND/CTA submission timeline with FDA or EMA requirements specific to the modality
- Dose rationale framework (MABEL/NOAEL) with the data each agency expects to see
- Pre-IND meeting strategy, briefing document outline, and question list
- Nonclinical package gap analysis with study-specific remediation steps
Board-ready deliverables
- Visual timeline with milestones and decision gates
- Risk register with specific mitigations, not generic categories
- Gap closure plan with studies, timelines, and costs
- Executive summary ready for board decks and investor conversations
How the work runs
Phases
Scope shaped on the scoping call.
Scope
Where the program stands, which decisions are in front of it, and how deep the plan needs to go.
Target and indication read
Unmet need, competitive landscape, and regulatory precedent specific to the modality and indication.
Study plan and regulatory alignment
Study-by-study plan with models, endpoints, timelines, budgets, CRO shortlists, and regulatory path alignment.
Debrief and handoff
Walk-through of the plan. Board-ready deliverables packaged. Optional follow-through on CRO negotiation or regulatory prep.
Who it's for
Audience
Seed and Series A biotech
Lead candidate and a fundraise on the calendar. A study-level development plan suitable for execution and investor conversations.
Academic spinouts
Promising discovery data, but no development plan that translates the science into timelines, budgets, and risk-adjusted milestones.
Multi-program companies
Multiple programs under capital constraint. Study-level plans with budget projections support defensible portfolio allocation.
FAQ
Frequently asked questions
§ / More capabilities
Other capabilities
Competitive Intelligence
Read the field. Study by study, with a source trail on every claim.
Read more →Portfolio & Indication Strategy
Choose among options. Scored candidates, head-to-head matrix, written rationale.
Read more →Investor/Partner Readiness
Prepare the package. Independent review of what investors and partners will see.
Read more →§ / Engage
Contact
BridgeLine Translational. A remote practice, serving biotech clients worldwide.